NicOx SA

NicOx SA

NicOx SA

Overview
Date Founded

1996

Headquarters

Drakkar 2 - Bât D,2405 route des Dolines,Sophia-Antipolis, Provence-Alpes-Cote-dAzur 06560

Type of Company

Public

Employees (Worldwide)

34

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Nicox SA is an ophthalmology company, which engages in developing innovative solutions to help maintain vision and improve ocular health. Its products include Zerviate, and Vyzulta. The company was founded by Piero Del Soldato, Michele Garufi and Elizabeth Marie Robinson on February 15, 1996 and is headquartered in Sophia-Antipolis, France.

Contact Data
Trying to get in touch with decision makers at NicOx SA? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Co-Founder, Chairman & Chief Executive Officer

General Counsel & Head of Legal

Executive Vice President & Chief Business Officer

Executive Vice President, Head of Research & Development

Chief Scientific Advisor

Vice President, Finance

Head of Discovery

Board of Directors

Co-Founder, Chairman & Chief Executive Officer at NicOx SA

Director at Glaucoma Research Foundation

Chief Financial Officer & Executive Vice President, Corporate Development at Evolus, Inc.

Former Executive Chairman at Aciex Therapeutics, Inc.

Chief Executive Officer at IDS

Director & Senior Global Pharmaceutical Executive at Orasis Pharmaceuticals Ltd.

Paths to NicOx SA
Potential Connections via
Relationship Science
You
NicOx SA
Recent Transactions
Details Hidden

GHO Capital Partners LLP purchases Nicox SA /European & International Commercial Ops from NicOx SA

Details Hidden

Bausch Health Cos., Inc. purchases B+L Diagnostics, Inc. from NicOx SA

Details Hidden

NicOx SA purchases Aciex Therapeutics, Inc. from HealthCare Ventures LLC, New Enterprise Associates, Bay City Capital LLC

Transaction Advisors
Investment Advisor

Advised onNicOx SA purchases Laboratories DOLIAGE SAS

Legal Advisor

Advised onNicOx SA purchases Aciex Therapeutics, Inc. from HealthCare Ventures LLC, New Enterprise Associates, Bay City Capital LLC

Investment Advisor

Advised onNicOx SA purchases Altacor Ltd.

Legal Advisor

Advised onNicOx SA purchases Aciex Therapeutics, Inc. from HealthCare Ventures LLC, New Enterprise Associates, Bay City Capital LLC

Advisors & Consultants
Legal Advisor

Partner at Clifford Chance LLP

Legal Advisor

Former Partner at Clifford Chance LLP

Consultant

Chief Scientific Advisor at NicOx SA

Clients

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Ora, Inc. provides ophthalmic services. It engages in the provision of ophthalmic services and it specializes in allergy, allergic rhinitis, dry-eye, retina, anti-infective, anti-inflammatory, glaucoma, drug delivery, and ophthalmic devices. The firm offers development services including preclinical models, clinical research and development, regulatory strategy, statistics and data management, medical writing, and marketing and advertising. The company was founded by Mark Barry Abelson in 1985 and is headquartered in Andover, MA.

Key Stats and Financials As of 2018
Market Capitalization
$149M
Total Enterprise Value
$126M
Earnings Per Share
$-0.62
Revenue
$4.72M
Net Profit
$-18.4M
EBITDA
$-21.7M
EBITDAMargin
-459.49%
Total Debt
$85K
Total Equity
$114M
Enterprise Value Sales
26.78x
TEVNet Income
-6.87x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
-22.06%
Five Year Compounded Annual Growth Rate Of Revenue
44.57%
Investments
Details Hidden

Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom.

Suppliers
Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Competitors
Sun Pharmaceutical Industries Ltd. Pharmaceuticals - Mumbai, MA

Sun Pharmaceutical We are an international speciality pharma company, with a large presence in the US and India, and a footprint across 41 other markets. In the US, which is our largest market, we have built a strong pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio. In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, diabetology, ophthalmology, orthopedics etc. We are market leaders in speciality therapy areas in India. We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 5th largest by prescription sales, a rank that we have retained over a decade. (IMS ORG Stockist Audit, March. 2012) Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics

Allergan Plc Pharmaceuticals - Dublin, DU

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Mallinckrodt Plc Pharmaceuticals - Staines-Upon-Thames, SU

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Staines-Upon-Thames, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by NicOx SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of NicOx SA's profile does not indicate a business or promotional relationship of any kind between RelSci and NicOx SA.